2 Stocks Taking a Gut Shot: Harmony Gold Mining Company Limited (HMY), Spectrum Pharmaceuticals, Inc. (SPPI)

Harmony Gold Mining Company Limited (NYSE:HMY) recent drop took place on significantly less volume which dipped to nearly 2.72 million contracts on 07-Nov-17 versus its daily average of 3.3 million. The first sale was made at $1.8 but later the stock became weaker, and closed with a fall of -4.35%. It was last traded at $1.76 apiece.

Harmony Gold Mining Company Limited (HMY): Hold Candidate With 6.82% Upside Potential

Harmony Gold Mining Company Limited is maintained at an average hold rating by 3 stock analysts, and there are at least 1.16% of shares outstanding that are currently legally short sold. The shares went down by -8.33% in value last month. Year-to-date it plunged -20.36%. Analysts are turning out to be more pessimistic than before, with 0 of analysts who cover Harmony Gold Mining Company Limited (NYSE:HMY) advice adding it to buy candidate list. Wall Street experts also assign a $1.88 price target on Harmony Gold Mining Company Limited, pointing towards a 6.82% rally from current levels. The stock is trading for about -48.99% less than its 52-week high.

HMY Adds 1.73% In A Week

This company shares (HMY) so far managed to recover 12.82% since collapsing to its 52-week low. Over a month, it has seen its stock price volatility to stay at 3.88% while shortening the period to a week, volatility was 3.29%. The share price has yet to cross its 20 days moving average, floating at a distance of -0.4% and sits -6.3% lower versus its 50 days moving average. When looking at the past five sessions, the stock returned 1.73% gains and is down by -15.7% compared with its 200-day moving average of $1.89. Also, Harmony Gold Mining Company Limited (HMY) needs to overturn a -44.83% decrease it experienced over the past twelve months.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Consensus Call At 1.3

As regular trading ended, Spectrum Pharmaceuticals, Inc. (SPPI) stock brought in a -$0.22 drop to $19. The day started at a price of $19.13 but then traded as high as $19.38 before giving part of the gains back. As for this week, analysts appear content to stick with their bright outlook with the consensus call at 1.3. Spectrum Pharmaceuticals, Inc. is given 2 buy-equivalent recommendations, 0 sells and 0 holds. The company shares sank -13.44% from their peak of $21.95 and now has a $1.75 billion market value of equity.

Spectrum Pharmaceuticals, Inc. Could Grow 35.11% More

SPPI’s mean recommendation on Reuter’s scale slipped from 1.5 thirty days ago to 1.33 now, which indicates a buy consensus from the analyst community. They see Spectrum Pharmaceuticals, Inc. (SPPI) price hitting a mean target of $25.67 a share, meaning the stock still has potential that could lift the price another 35.11% Also, the recent close suggests the stock is underpriced by 68.42% compared to the most bullish target.

Spectrum Pharmaceuticals, Inc. (SPPI) Returns 328.89% This Year

The company had seen its current volume reaching at 1.01 million shares in the last trade. That compares with the recent volume average of 1.83 million. At the close of regular trading, its last week’s stock price volatility was 5.89% which for the month reaches 5.54%. Spectrum Pharmaceuticals, Inc. dipped to as low as $18.66 throughout the day and has returned 328.89% in this year. At one point in the past year, the shares traded as low as $3.46 but has recovered 449.13% since then.

Previous articleWhy Receiving Plenty Of Attention? – Corcept Therapeutics Incorporated (CORT), Halozyme Therapeutics, Inc. (HALO)
Next articleNo More Impressive Technical Run? – Western Copper and Gold Corporation (WRN), Cerus Corporation (CERS)